

Table SIII. Systemic therapies included in the meta-analysis

Study	Intervention	Treatment categorization	Treatment duration (days)	Sample size in active treatment arm <i>n</i>	Sample size in control treatment arm <i>n</i>	Trial design and duration
Senapati et al., 2008 (17)	Primrose oil 500 mg vs. placebo	Herbal	140	29	36	Parallel
Cheng et al., 2011 (57)	Xiao-Feng-San vs. placebo	Herbal	56	47	24	Parallel
Fölster-Holst et al., 2006 (58)	L. rhamnosus strain GG (LGG) vs. placebo	Probiotic	56	26	27	Parallel
Koch et al., 2008 (59)	Docosahexaenoic acid 5.4 g vs. placebo	Dietary supplementation	56	21	23	Parallel
Hannuksela et al., 1993 (56)	Cetirizine 40 mg vs. placebo	Anti-histamine	28	47	42	Parallel
Leung et al., 1990 (52)	Thymopentin vs. placebo	Immunosuppressant	42	48	52	Parallel
Stiller et al., 1994 (53)	Thymopentin vs. placebo	Immunosuppressant	84	20	19	Parallel
Friedmann et al., 2007 (54)	Montelukast vs. placebo	Immunosuppressant	56	30	30	Parallel
Oldhoff et al., 2005 (55)	Mepolizumab 750 mg vs. placebo	Immunosuppressant	14	20	23	Parallel
Hanifin et al., 1993 (66)	rIFN- γ vs. placebo	Immunosuppressant	84	40	43	Parallel